Table 1.
C-HTN, Controlled Hypertension; NAION, Non Arteritic Isquemic Optic Neuropathy; BRAO, Branch Retinal Artery Occlusion; CRAO, Central Retinal Artery Occlusion; BRVO, Branch Retinal Vein Occlusion, CRVO, Central Retinal Vein Occlusion; NA Not available* Didn't know the exact date when they passed COVID-19 as they were asymptomatic; IRNL, Internal retinal nasal layers; RNFL, Retinal nerve fiber layers; MA, Macular atrophy; ME, Macular edema; N, Normal; VA, Visual Acuity; VEGF, Vascular Endothelial Growth Factor; PRP, Panretinalphotocoagulation.
| Age/Gender | Risk Factors | Type of retinal/optic nerve vascular disease | COVID symptoms | Mean time (months) between COVID diagnosis and ocular symptoms | Hospitalization required by COVID? | OCT findings | Initial VA LogMAR | Treatment | Final VA LogMAR | |
|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 39, F | NO | NAION | No | NA* | No | Reduction in the RNFL | 1,3 | No | 1,3 |
| Case 2 | 58, M | NO | NAION | Yes | 4 | No | Reduction in the RNFL | 0,39 | No | 0,47 |
| Case 3 | 45, M | NO | BRAO | No | NA* | No | Thickenning of the IRNL | 0 | No | 0 |
| Case 4 | 61, F | C-HTN | CRAO | Yes | 5 | Yes | MA | 1 | No | 1 |
| Case 5 | 60, F | NO | CRAO | No | NA* | No | MA | 1,3 | No | 1,3 |
| Case 6 | 56, F | C-HTN | CRAO | No | NA* | No | MA | 2 | No | 2 |
| Case 7 | 46, M | NO | CRAO | Yes | 4 | No | MA | 1,3 | No | 1,3 |
| Case 8 | 27, M | NO | BRVO, BRAO | Yes | 4 | No | ME | 0,17 | Anti-VEGF | 0,09 |
| Case 9 | 60, F | C-HTN | CRVO, BRAO | No | 4 | No | ME | 1 | Anti-VEGF/PRP | 0,69 |
| Case 10 | 43, F | NO | CRVO | Yes | 4 | No | ME | 0,3 | Anti-VEGF | 0,17 |
| Case 11 | 46, M | C-HTN | CRVO | Yes | 4 | No | ME | 0,17 | Anti-VEGF | 0,09 |
| Case 12 | 45, M | NO | CRVO | No | 3 | No | ME | 0,17 | Anti-VEGF | 0,09 |
| Case 13 | 47, M | NO | CRVO | Yes | 4 | No | ME | 0,09 | Anti-VEGF | 0 |
| Case 14 | 57, M | C-HTN | CRVO | No | NA* | No | ME | 0,3 | Anti-VEGF | 0 |
| Case 15 | 45, M | NO | CRVO | Yes | 5 | No | N | 0,3 | Anti-VEGF | 0,09 |